Nxera Pharma(OTC) SOLTF

Market Cap$530.67M

Since IPO (2014)-87%

5 Year-65%

1 Year-8%

1 Month-10%

$5.73

+0.00%

+0.00Today

Nxera Pharma last closing stock price
Metric	Price	Date
Last close	USD 5.73	2026-07-31

Nxera Pharma stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+1.74%	USD 5.63	2026-07-22
1 month	-10.05%	USD 6.37	2026-06-22
3 month	-14.35%	USD 6.69	2026-05-01
Year to date	+4.56%	USD 5.48	2025-12-29
1 year	-7.58%	USD 6.20	2025-07-30
3 year	-56.69%	USD 13.23	2023-08-01
5 year	-64.91%	USD 16.33	2021-07-15
Since inception	-86.75%	USD 43.25	2014-08-29

Nxera Pharma Financials at a Glance

Market Cap

$530.67M

Revenue (TTM)

¥34.40B

Net Income (TTM)

-¥10.00B

EPS (TTM)

-$0.75

P/E Ratio

-7.79

Dividend

$0.00

Beta (Volatility)

0.06 (Low)

Dividend

$0.00

Beta (Volatility)

0.06 (Low)

Price

$5.73

Volume

100

Open

$5.73

Price

$5.73

Volume

100

Open

$5.73

Previous Close

$5.73

Daily Range

$5.73 - $5.73

52-Week Range

$4.90 - $7.94

Estimated Earnings Date

Aug 7, 2026

Dividend

$0.00

Beta (Volatility)

0.06 (Low)

Price

$5.73

Volume

100

Open

$5.73

Previous Close

$5.73

Daily Range

$5.73 - $5.73

52-Week Range

$4.90 - $7.94

Estimated Earnings Date

Aug 7, 2026

SOLTF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Nxera Pharma

Nxera Pharma Co., Ltd. is a biopharmaceutical enterprise focused on developing and commercializing pharmaceutical products globally. The company operates in multiple countries, including Japan, Switzerland, the United States, Bermuda, and the United Kingdom, offering a diverse range of established treatments.

Products and Services

Ultibro/Breezhaler and Seebri/Breezhaler for chronic obstructive pulmonary disease
Enerzair and Breezhaler for asthma management
ORAVI for oropharyngeal candidiasis and PIVLAZ for cerebral vasospasm

Growth Outlook

Strong R&D pipeline with investigational compounds for various conditions
Strategic alliances with industry leaders like AbbVie and Pfizer
Expansion into new therapeutic areas, including immuno-oncology and neuropsychiatry

Financial Highlights

Recent quarterly revenue of 11.33 billion JPY, a significant increase
Gross profit margin of 90% in the latest quarter
Current ratio of 2.61, indicating strong liquidity

Nxera Pharma Co., Ltd. has established itself as a key player in the biotechnology sector, with a focus on innovative treatments and a robust pipeline of investigational compounds. The company's strategic partnerships with major industry players enhance its potential for growth and market expansion. Recent financial performance indicates a positive trajectory, with substantial revenue growth and a strong gross profit margin. The liquidity position remains solid, providing a foundation for future investments in research and development. As Nxera Pharma continues to advance its product offerings and explore new therapeutic areas, it presents an intriguing opportunity for potential investors interested in the biopharmaceutical landscape.

AI Generated • Jul 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

382

CEO

Chris Cargill

Website

www.nxera.life

Headquarters

Tokyo, TY 102-0083, JP

SOLTF Financials

Key Financial Metrics (TTM)

Gross Margin

77.50%

Operating Margin

-6.59%

Net Income Margin

-29.15%

Return on Equity

-15.58%

Return on Capital

-6.83%

Return on Assets

-7.48%

Earnings Yield

-12.84%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$530.67M

Shares Outstanding

92.61M

Volume

100

Avg. Volume

605.159

Financials (TTM)

Gross Profit

¥26.65B

Operating Income

-¥2.57B

EBITDA

¥3.09B

Operating Cash Flow

-¥4.99B

Capital Expenditure

-¥646.04M

Free Cash Flow

-¥5.63B

Cash & ST Invst.

¥11.67B

Total Debt

¥56.18B

Nxera Pharma Performance Analysis

Nxera Pharma annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	JPY 118,370,543	-26.6%
2023	2023-12-31	JPY 90,788,244	-23.3%
2024	2024-12-31	JPY 190,336,436	109.6%
2025	2025-12-31	JPY 197,961,871	4.0%

Nxera Pharma sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	27.2%
Q3	2025-09-30	-18.9%
Q4	2025-12-31	13.5%
Q1	2026-03-31	45.7%

Nxera Pharma annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	JPY 0.04	-68.8%
2023	2023-12-31	JPY -0.62	N/A
2024	2024-12-31	JPY -0.36	-42.6%
2025	2025-12-31	JPY -0.93	160.7%

Nxera Pharma sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	-211.8%
Q3	2025-09-30	31.7%
Q4	2025-12-31	-379.0%
Q1	2026-03-31	120.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

¥11.33B

+70.5%

Gross Profit

¥10.20B

+102.9%

Gross Margin

90.07%

N/A

Market Cap

$530.67M

N/A

Market Cap/Employee

$1.39M

N/A

Employees

382

N/A

Net Income

¥1.80B

+337.4%

EBITDA

¥4.67B

+520.4%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

¥11.67B

-66.1%

Total Debt

¥56.18B

-15.2%

Accounts Receivable

¥14.15B

+217.2%

Inventory

¥11.23B

+28.1%

Long Term Debt

¥49.44B

-17.0%

Short Term Debt

¥6.74B

+0.8%

Return on Assets

-7.48%

N/A

Return on Invested Capital

-1.90%

N/A

Free Cash Flow

-¥1.97B

-490.9%

Operating Cash Flow

-¥1.66B

-371.5%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

VBIZFViva Biotech Holdings

VBIZFViva Biotech Holdings$0.16+0.00%

BPMUFBasilea Pharmaceutica AG

BPMUFBasilea Pharmaceutica AG$60.28+0.00%

BOVNFBioInvent International AB (publ)

BOVNFBioInvent International AB (publ)$3.29+0.00%

GSGTFGenSight Biologics S.A.

GSGTFGenSight Biologics S.A.$0.09+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NVDANvidia

NVDANvidia$200.75+0.03%

AAPLApple

AAPLApple$308.91-0.07%

AMZNAmazon

AMZNAmazon$271.58+0.15%

INTCIntel

INTCIntel$90.20-0.01%

FCUVFocus Universal

FCUVFocus Universal$11.60+5.17%

NOKNokia

NOKNokia$9.14+0.01%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$64.62+0.02%

Questions About SOLTF

What is the current price of Nxera Pharma?

Nxera Pharma is trading at $5.73 per share.

What is the 52-week range for Nxera Pharma?

Over the past 52 weeks, Nxera Pharma has traded between $4.90 and $7.94.

How much debt does Nxera Pharma have?

As of the most recent reporting period, Nxera Pharma reported total debt of ¥350.93M.

How much cash does Nxera Pharma have on hand?

Nxera Pharma reported ¥72.90M in cash and cash equivalents in its most recent financial results.

What is Nxera Pharma’s dividend yield?

Nxera Pharma does not currently have a dividend yield.

Nxera Pharma(OTC) SOLTF

Nxera Pharma Financials at a Glance

SOLTF News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Nxera Pharma

SOLTF Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Nxera Pharma Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About SOLTF

What is the current price of Nxera Pharma?

What is the 52-week range for Nxera Pharma?

How much debt does Nxera Pharma have?

How much cash does Nxera Pharma have on hand?

What is Nxera Pharma’s dividend yield?

Premium Investing Services